DLC1 Antikörper (C-Term)
Kurzübersicht für DLC1 Antikörper (C-Term) (ABIN630519)
Target
Alle DLC1 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- C-Term
-
Spezifität
- DLC1 antibody was raised against the C terminal of DLC1
-
Aufreinigung
- Affinity purified
-
Immunogen
- DLC1 antibody was raised using the C terminal of DLC1 corresponding to a region with amino acids NLAVCLAPSLFHLNTLKRENSSPRVMQRKQSLGKPDQKDLNENLAATQGL
-
-
-
-
Applikationshinweise
-
WB: 0.5 µg/mL
Optimal conditions should be determined by the investigator. -
Kommentare
-
DLC1 Blocking Peptide, (ABIN5613215), is also available for use as a blocking control in assays to test for specificity of this DLC1 antibody
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of DLC1 antibody in PBS
-
Konzentration
- Lot specific
-
Buffer
- PBS
-
Handhabung
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
-
- DLC1 (Deleted in Liver Cancer 1 (DLC1))
-
Andere Bezeichnung
- DLC1
-
Hintergrund
- This gene is deleted in the primary tumor of hepatocellular carcinoma. It maps to 8p22-p21.3, a region frequently deleted in solid tumors. It is suggested that this gene is a candidate tumor suppressor gene for human liver cancer, as well as for prostate, lung, colorectal, and breast cancers. DLC1 functions as a GTPase-activating protein specific for Rho and an activator of PLCD1 in vivo and induces morphological changes and detachment through cytoskeletal reorganization.
-
Molekulargewicht
- 52 kDa (MW of target protein)
-
Pathways
- Tube Formation, Positive Regulation of Endopeptidase Activity
Target
-